Medicxi backs Chi­nese biotech's next-gen KRAS G12C drug with $40M in­jec­tion

The search for next-gen­er­a­tion KRAS drugs that can do what Am­gen and Bris­tol My­ers Squibb’s med­i­cines can’t has led to Medicxi’s first-ever in­vest­ment in Chi­na …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER